&w=1200&q=75)
New Experimental Hepatitis B Treatment Shows Promising Results
STAT+: Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show
Image: Stat
An experimental treatment, bepirovirsen, has achieved a functional cure for nearly 20% of chronic hepatitis B patients in clinical trials, significantly surpassing the effectiveness of current treatments. This advancement is crucial as hepatitis B affects 250-300 million people globally and causes serious health issues.
- 01Bepirovirsen, developed by GSK, achieved functional cures in 20% and 19% of participants in two clinical trials.
- 02Current nucleoside analogue treatments result in functional cures for only 1% to 3% of patients.
- 03Hepatitis B is responsible for approximately 1 million deaths annually worldwide.
- 04Chronic hepatitis B infections affect between 250 million to 300 million people globally.
- 05No patients receiving placebo achieved a functional cure in the trials.
Advertisement
In-Article Ad
In recent clinical trials, an experimental medication known as bepirovirsen demonstrated the ability to achieve a functional cure for hepatitis B in nearly 20% of patients with chronic infections. This is a significant improvement over existing nucleoside analogue treatments, which only result in functional cures for 1% to 3% of patients. Hepatitis B is a serious global health issue, affecting 250 to 300 million individuals and causing around 1 million deaths each year due to complications such as cirrhosis and liver cancer. The trials revealed that no patients receiving a placebo reached a functional cure, highlighting the potential effectiveness of bepirovirsen.
Advertisement
In-Article Ad
If approved, bepirovirsen could significantly improve treatment outcomes for hepatitis B patients, particularly in regions heavily affected by the virus.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new hepatitis B treatment results?
Connecting to poll...
More about GSK
Read the original article
Visit the source for the complete story.